NCT06752759View on ClinicalTrials.gov

Nebulized Ketamine for the Treatment of Major Depressive Disorder in an Inpatient Setting

PHASE3RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 16, 2024

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions
Severe DepressionModerate DepressionKetamineMidazolamPeripheral Nervous System AgentsCentral Nervous System AgentsNeurotransmitter AgentsPhysiologic Effects of DrugsSensory System AgentsAnalgesics, Non-NarcoticAnti-Inflammatory Agents, Non-SteroidalDepressive SymptomHypnotics and SedativesAnti-anxiety AgentsTranquilizing AgentsPsychotropic DrugsAnesthetics AgentGABA ModulatorsGABA Agents
Interventions
DRUG

nebulized ketamine

The formulation of the study drug is administered via nebulizer in which the participants inhales the study drug. The dosage is calculated by body weight (1.5mg/kg).

Trial Locations (1)

11219

RECRUITING

Maimonides Medical Center, Brooklyn

All Listed Sponsors
lead

Theresa Jacob, PhD, MPH

OTHER